{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Radiographic reduction in size of non-irradiated extramedullary lesions.","groups":[{"description":"Avelumab 800 mg IV every two weeks in combination with radiation therapy\n\nAvelumab: Avelumab 800 mg intravenous (IV) over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle\n\nExternal beam radiotherapy: 5 gray (Gy) per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy","id":"OG000","title":"1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy"}],"populationDescription":"This outcome measure was not evaluated due to study closure.","reportingStatus":"POSTED","timeFrame":"end of study","title":"Percent Reduction in Size of On-irradiated Extramedullary Lesions","type":"SECONDARY"}